Slanar O[au] - Search Results

Year	Number of Results
1997	1
2000	1
2001	2
2002	2
2005	2
2006	7
2007	3
2008	3
2009	3
2010	8
2011	4
2012	6
2013	6
2014	3
2015	7
2016	4
2017	11
2018	9
2019	13
2020	17
2021	15
2022	25
2023	17
2024	8

1

Implications of rituximab pharmacokinetic and pharmacodynamic alterations in various immune-mediated glomerulopathies and potential anti-CD20 therapy alternatives.

Hartinger JM, Kratky V, Hruskova Z, Slanar O, Tesar V. Hartinger JM, et al. Among authors: slanar o. Front Immunol. 2022 Nov 7;13:1024068. doi: 10.3389/fimmu.2022.1024068. eCollection 2022. Front Immunol. 2022. PMID: 36420256 Free PMC article. Review.

2

Pharmacokinetics of Dasatinib.

Hořínková J, Šíma M, Slanař O. Hořínková J, et al. Among authors: slanar o. Prague Med Rep. 2019;120(2-3):52-63. doi: 10.14712/23362936.2019.10. Prague Med Rep. 2019. PMID: 31586504 Free article. Review.

3

Factors Affecting Drug Exposure after Inhalation.

Nováková A, Šíma M, Slanař O. Nováková A, et al. Among authors: slanar o. Prague Med Rep. 2022;123(3):129-139. doi: 10.14712/23362936.2022.13. Prague Med Rep. 2022. PMID: 36107443 Free article. Review.

4

Effects of Cannabidiol in Inflammation: A Review of Pre-clinical and Clinical Findings.

Sklenárová M, Šíma M, Slanař O. Sklenárová M, et al. Among authors: slanar o. Prague Med Rep. 2023;124(3):216-229. doi: 10.14712/23362936.2023.17. Prague Med Rep. 2023. PMID: 37736946 Free article. Review.

5

Dose Optimization and Targeting Strategies of Anti-Infective Agents.

Šíma M, Slanař O. Šíma M, et al. Among authors: slanar o. Pharmaceutics. 2023 Jul 3;15(7):1870. doi: 10.3390/pharmaceutics15071870. Pharmaceutics. 2023. PMID: 37514056 Free PMC article.

6

Targeting Keap1/Nrf2/ARE signaling pathway in multiple sclerosis.

Michaličková D, Hrnčíř T, Canová NK, Slanař O. Michaličková D, et al. Among authors: slanar o. Eur J Pharmacol. 2020 Apr 15;873:172973. doi: 10.1016/j.ejphar.2020.172973. Epub 2020 Feb 1. Eur J Pharmacol. 2020. PMID: 32017935 Review.

7

Pharmacogenetics in clinical practice.

Bakhouche H, Slanař O. Bakhouche H, et al. Among authors: slanar o. Prague Med Rep. 2012;113(4):251-61. doi: 10.14712/23362936.2015.8. Prague Med Rep. 2012. PMID: 23249656 Review.

8

Dasatinib anhydrate containing oral formulation improves variability and bioavailability in humans.

Hofmann J, Bartůněk A, Hauser T, Sedmak G, Beránek J, Ryšánek P, Šíma M, Slanař O. Hofmann J, et al. Among authors: slanar o. Leukemia. 2023 Dec;37(12):2486-2492. doi: 10.1038/s41375-023-02045-1. Epub 2023 Oct 3. Leukemia. 2023. PMID: 37789147 Free PMC article.

9

Explaining dissolution properties of rivaroxaban cocrystals.

Hriňová E, Skořepová E, Čerňa I, Královičová J, Kozlík P, Křížek T, Roušarová J, Ryšánek P, Šíma M, Slanař O, Šoóš M. Hriňová E, et al. Among authors: slanar o. Int J Pharm. 2022 Jun 25;622:121854. doi: 10.1016/j.ijpharm.2022.121854. Epub 2022 May 25. Int J Pharm. 2022. PMID: 35623488

10

Changes in Parameters of Oxidative Stress, Immunity, and Behavior in Endurance Athletes During a Preparation Period in Winter.

Michalickova D, Minic R, Kotur-Stevuljevic J, Andjelkovic M, Dikic N, Kostic-Vucicevic M, Slanar O, Djordjevic B. Michalickova D, et al. Among authors: slanar o. J Strength Cond Res. 2020 Oct;34(10):2965-2973. doi: 10.1519/JSC.0000000000002780. J Strength Cond Res. 2020. PMID: 30199454

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

150 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

150 results

Results by year